NASDAQ:CNAT Conatus Pharmaceuticals (CNAT) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.47▼$0.5650-Day Range$0.56▼$1.3452-Week Range$0.23▼$1.07Volume553,713 shsAverage Volume1.28 million shsMarket Capitalization$18.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Conatus Pharmaceuticals (NASDAQ:CNAT) StockConatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.Read More CNAT Stock News HeadlinesApril 3, 2023 | thestreet.comConatus Pharmaceuticals (CNAT) Stock Soars on Positive Liver Drug Trial ResultsAugust 30, 2022 | thestreet.com2015 Biotech Drug/Stock Outlook: Here's What You Need to KnowSeptember 24, 2023 | Chaikin Analytics (Ad)Get Your Cash Out of U.S. Banks ImmediatelyMan who predicted 2023 bank run warns a historic financial reset is coming. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.September 6, 2020 | bloomberg.comConatus Pharmaceuticals' Emricasan Dosed in First Patient in Mayo Clinic Phase 2 Trial in Severe Alcoholic Hepatitis PopulationAugust 22, 2020 | ca.finance.yahoo.comCNAT Jan 2021 2.500 callAugust 20, 2020 | ca.finance.yahoo.comCNAT Oct 2020 2.500 callAugust 1, 2020 | markets.businessinsider.comNews for Conatus Pharmaceuticals IncJuly 23, 2020 | www.bloomberg.comConatus Pharmaceuticals Announces Upcoming Oral Presentation at EASL Annual MeetingSeptember 24, 2023 | Chaikin Analytics (Ad)Get Your Cash Out of U.S. Banks ImmediatelyMan who predicted 2023 bank run warns a historic financial reset is coming. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.May 27, 2020 | seekingalpha.comHistogen completes tie-up with Conatus PharmaMay 18, 2020 | finance.yahoo.comLeading Independent Proxy Advisory Firms Recommend Conatus Pharmaceuticals Shareholders Vote in Favor of its Merger with Histogen and the Required Reverse Stock SplitMay 14, 2020 | finance.yahoo.comHistogen Publishes Preclinical Data on its HST 004 Spinal Disc ProgramMay 11, 2020 | finance.yahoo.comHistogen Receives US FDA IND Approval to Initiate Phase 1b/2a Trial of HST 001 in Androgenic AlopeciaMay 7, 2020 | finance.yahoo.comThe Conatus Pharmaceuticals Special Meeting of Stockholders Seeking Approval for Proposed Merger with Histogen Inc. will Reconvene on May 21, 2020May 1, 2020 | finance.yahoo.comConatus Pharmaceuticals Reports First Quarter 2020 Financial Results and Strategic Process UpdateApril 26, 2020 | www.fool.comConatus PharmaceuticalsApril 20, 2020 | finance.yahoo.comHistogen Announces Investigational Device Exemption Application for HST 002April 15, 2020 | finance.yahoo.comHistogen Publishes New Preclinical Data on its HST 003 Orthopedic ProgramApril 6, 2020 | finance.yahoo.comHistogen Announces Investigational New Drug Application Amendment for HST 001March 25, 2020 | www.marketwatch.comConatus Pharmaceuticals Inc.February 6, 2020 | finance.yahoo.comHistogen to Present at BIO CEO & Investor ConferenceJanuary 29, 2020 | www.benzinga.com12 Healthcare Stocks Moving In Wednesday's Pre-Market SessionJanuary 28, 2020 | seekingalpha.comConatus to merge with HistogenJanuary 28, 2020 | www.benzinga.comConatus Pharmaceuticals and Histogen Enter into Definitive Merger AgreementJanuary 22, 2020 | www.msn.com98 Biotechnology Stocks Moving In Wednesday's SessionJanuary 22, 2020 | www.benzinga.com116 Healthcare Stocks Moving In Wednesday's SessionNovember 18, 2019 | finance.yahoo.comConatus Pharmaceuticals Appoints Kathy Scott as Independent Board MemberSee More Headlines Receive CNAT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Conatus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CNAT Company Calendar Last Earnings5/01/2020Today9/24/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical Preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CNAT CUSIPN/A CIK1383701 Webwww.conatuspharma.com Phone858-376-2600FaxN/AEmployees30Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,390,000.00 Net Margins-52.42% Pretax MarginN/A Return on Equity-48.22% Return on Assets-39.32% Debt Debt-to-Equity RatioN/A Current Ratio16.28 Quick Ratio16.28 Sales & Book Value Annual Sales$21.72 million Price / Sales0.84 Cash FlowN/A Price / Cash FlowN/A Book Value$0.53 per share Price / Book1.03Miscellaneous Outstanding Shares33,170,000Free FloatN/AMarket Cap$18.14 million OptionableOptionable Beta1.84 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Steven J. Mento (Age 67)Co-Founder, Pres, CEO & Director Dr. Keith W. Marshall MBA (Age 51)Ph.D., Exec. VP, COO & CFO Dr. David T. Hagerty (Age 64)Exec. VP of Clinical Devel. Dr. Alfred P. Spada (Age 61)Co-Founder, Exec. VP of R&D and Chief Scientific Officer Mr. Alan R. EngbringExec. Director of Investor Relations & Corp. CommunicationsKey CompetitorsAeterna ZentarisNASDAQ:AEZSDominariNASDAQ:DOMHAcelRx PharmaceuticalsNASDAQ:ACRXRVL PharmaceuticalsNASDAQ:RVLPImpel PharmaceuticalsNASDAQ:IMPLView All Competitors CNAT Stock - Frequently Asked Questions How were Conatus Pharmaceuticals' earnings last quarter? Conatus Pharmaceuticals Inc (NASDAQ:CNAT) issued its quarterly earnings results on Friday, May, 1st. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.10). Conatus Pharmaceuticals had a negative trailing twelve-month return on equity of 48.22% and a negative net margin of 52.42%. What other stocks do shareholders of Conatus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Conatus Pharmaceuticals investors own include KNOT Offshore Partners (KNOP), Trevena (TRVN), PPL (PPL), (CASC) (CASC), Vaxart (VXRT), Antares Pharma (ATRS), Dextera Surgical (DXTR), Novavax (NVAX), Exelixis (EXEL) and Geron (GERN). What is Conatus Pharmaceuticals' stock symbol? Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT." What is Conatus Pharmaceuticals' stock price today? One share of CNAT stock can currently be purchased for approximately $0.55. How much money does Conatus Pharmaceuticals make? Conatus Pharmaceuticals (NASDAQ:CNAT) has a market capitalization of $18.14 million and generates $21.72 million in revenue each year. How can I contact Conatus Pharmaceuticals? Conatus Pharmaceuticals' mailing address is 16745 W. Bernardo Dr. Suite 250, San Diego CA, 92127. The official website for the company is www.conatuspharma.com. The biotechnology company can be reached via phone at 858-376-2600 or via email at aengbring@conatuspharma.com. This page (NASDAQ:CNAT) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conatus Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.